MSK-ACCESS (liquid biopsy, generic)
Overview
MSK-ACCESS is a targeted next-generation sequencing panel for cell-free DNA from plasma, used at MSK for ctDNA profiling. The canonical 129-gene version is ACCESS129. This page serves as a generic slug used where the specific version is not distinguished PMID:38922339.
Used by
- PMID:38922339 — MSK-ACCESS was one of three sequencing platforms (alongside MSK-IMPACT and MSK-Fusion) used to sequence 97,024 samples from 69,337 patients at MSK between January 2014 and November 2022; samples contributed to identification of 212 patients with oncogenic BRAF fusions across 52 histologies PMID:38922339.
- PMID:39289779 — MSK-ACCESS (ACCESS129, 129-gene cfDNA panel) was applied to a paired plasma subset of 31 patients from the CSF ctDNA cohort to compare liquid-biopsy compartments; CSF VAFs were markedly higher than matched plasma (median 36.4% vs 2.3%, p<0.01); 75% of OncoKB level 1–3A alterations were shared between CSF and plasma PMID:39289779.
- PMID:40256659 — MSK-ACCESS (ACCESS129, 129-gene tumor-uninformed cfDNA panel, depth >15,000×) applied to pretreatment plasma from 201 patients with metastatic urothelial carcinoma in the CALGB 90601 trial; higher pretreatment ctDNA VAF (³√VAF₇₅ₚc) was independently associated with shorter OS (multivariable HR 2.51, p=0.009) and PFS; TERT promoter (57%), PIK3CA (11%), and ERBB2 (14%) alterations identified as candidate prognostic biomarkers PMID:40256659.
- Applied to 45 bladder cancer patients (primary tumor + metastasis + plasma cfDNA; ~20,000x raw coverage, 1,000x duplex); 20% of OncoKB-defined targetable mutations identified only by cfDNA; in 123-patient expanded analysis, 17% of targetable alterations exclusive to cfDNA PMID:36543146
Notes
- For the canonical 129-gene panel, see ACCESS129.
- Corpus-grown slug; the specific gene-panel version is
ACCESS129inschema/ontology/gene_panels.json.
Sources
This page was processed by crosslinker on 2026-05-04. - PMID:36543146
This page was processed by wiki-cli on 2026-05-05.